Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-09 4:19 pm Sale | 13G | Century Therapeutics, Inc. IPSC | Versant Venture Capital VI L.P. | 11,452,014 19.4% | -914,800 (-7.40%) | View |
| 2023-01-13 4:09 pm Sale | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 0 0% | -2,236,888 (Position Closed) | View |
| 2022-05-09 5:26 pm Purchase | 13D | Tempest Therapeutics, Inc. TPST | Versant Venture Capital VI L.P. | 2,118,644 20.5% | 940,173 (+79.78%) | View |
| 2022-02-10 8:39 pm Purchase | 13G | Century Therapeutics, Inc. IPSC | Versant Venture Capital VI L.P. | 12,366,814 22.6% | 12,366,814 (New Position) | View |
| 2022-02-10 7:41 pm Purchase | 13G | Tempest Therapeutics, Inc. TPST | Versant Venture Capital VI L.P. | 1,178,471 17.1% | 1,178,471 (New Position) | View |
| 2022-01-13 4:34 pm Unchanged | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.5% | 0 (Unchanged) | View |
| 2021-10-27 4:32 pm Unchanged | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | 0 (Unchanged) | View |
| 2021-07-09 4:43 pm Purchase | 13D | Graphite Bio, Inc. GRPH | Versant Venture Capital VI L.P. | 14,708,398 26.3% | 14,708,398 (New Position) | View |
| 2021-07-08 4:31 pm Purchase | 13D | Monte Rosa Therapeutics, Inc. GLUE | Versant Venture Capital VI L.P. | 6,799,115 15.3% | 6,799,115 (New Position) | View |
| 2021-06-21 4:44 pm Sale | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 1,457,937 3.8% | -485,979 (-25.00%) | View |
| 2021-05-24 4:27 pm Unchanged | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | 0 (Unchanged) | View |
| 2021-05-03 4:57 pm Sale | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 1,943,916 5.1% | -485,979 (-20.00%) | View |
| 2021-04-08 4:31 pm Purchase | 13D | LAVA Therapeutics N.V. LVTX | Versant Venture Capital VI L.P. | 3,407,157 13.4% | 3,407,157 (New Position) | View |
| 2021-04-05 4:33 pm Unchanged | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | 0 (Unchanged) | View |
| 2021-03-01 5:16 pm Sale | 13D | Oyster Point Pharma, Inc. OYST | Versant Venture Capital VI L.P. | 2,236,888 8.6% | -325,000 (-12.69%) | View |
| 2021-02-12 8:41 pm Sale | 13G | Akero Therapeutics, Inc. AKRO | Versant Venture Capital VI L.P. | 777,727 2.2% | -2,878,858 (-78.73%) | View |
| 2020-12-03 4:47 pm Sale | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 4,328,883 12% | -1,031,634 (-19.25%) | View |
| 2020-11-20 5:32 pm Sale | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 5,360,517 14.9% | -980,734 (-15.47%) | View |
| 2020-10-30 4:25 pm Purchase | 13D | Aligos Therapeutics, Inc. ALGS | Versant Venture Capital VI L.P. | 2,429,895 7.2% | 2,429,895 (New Position) | View |
| 2020-09-25 4:37 pm Sale | 13D | Black Diamond Therapeutics, Inc. BDTX | Versant Venture Capital VI L.P. | 6,341,251 17.7% | -457,424 (-6.73%) | View |